Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new ...

The FDA approved Lenacapavir, the first twice-a-year injection to prevent HIV, marking a historic step in public health.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Lenacapavir is already approved by the US Food and Drug Administration for the treatment of HIV infection in adults, in combination with other HIV antiretroviral medicines, and it’s estimated to ...

While lenacapavir does cost around $40,000 per patient per year in the U.S., this is the price for the drug when it is used as an HIV therapy, Blair Baumwell, a spokesperson for the company that ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Lenacapavir's cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating HIV transmission during sexual contact. But its cost could be an issue.